Lilly rides Mounjaro, Zepbound to better
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles
Russian theater director and playwright go on trial over a play authorities say justifies terrorism
TALLINN, Estonia (AP) — A Russian court on Monday opened the trial of a theater director and a playw2024-05-22Leverkusen moves 10 points clear atop Bundesliga
Bayer Leverkusen benefitted from Bayern Munich's draw and established a 10-point lead atop the s2024-05-22Eased processes aid tourism growth
Travelers wait to pass through immigration checkpoints in Beijing Capital International Airport2024-05-22Nanjing lose to Liaoning, miss CBA playoffs
Dominique Jones (L) of Xinjiang Flying Tigers competes during the 50th round match between Jilin Nor2024-05-22Messi in and Dybala out in Argentina squad for pre
BUENOS AIRES, Argentina (AP) — Lionel Messi is in and Paulo Dybala is out of Argentina’s squad for f2024-05-22- In the first-ever all-Chinese title fight in UFC history, Zhang Weili defeated Yan Xiaonan by unanim2024-05-22
atest comment